Chlamydiae pneumoniae Vaccines

Creative Biolabs is a forward-looking research institute as well as a leading custom service provider in the field of vaccine development. With our extensive experience and advanced platform, we have won good reputation among our worldwide customers for successfully accomplishing numerous challenging projects in vaccine development services for Chlamydiae pneumoniae vaccines. We guarantee the finest results for our customers all over the world.

Chlamydiae pneumoniae, belonging to the Chlamydiae family, is a Gram-negative obligate intracellular bacterium which causes acute and chronic infections of the upper and lower respiratory tracts. Recent studies show that it is associated with cardiovascular diseases, which may cause millions of infections each year, with a high morbidity and mortality rates in most countries around the world. During infection, it exhibits a biphasic replication cycle with two distinct developmental forms: the elementary body (EB) and the reticulate body (RB). Chlamydiae pneumoniae vaccine development has been a persisting global burden and considerable public health challenge for disease therapy. A number of Chlamydiae pneumoniae vaccines have been developed to avoid the dramatic increasing of C. pneumoniae infection cases.

The Infection Process of C. pneumoniae. – Creative Biolabs

Fig.1 The Infection Process of C. pneumoniae.

The Chlamydiae pneumoniae Vaccines

Chlamydiae pneumoniae is the common respiratory tracts pathogen in humans, which leads to a series of the upper and lower respiratory tracts diseases. It is necessary for vaccine development that prevents both respiratory infection and extra-respiratory spread of C. pneumoniae in adults, as well as in teenagers. Chlamydiae pneumoniae is usually diagnosed by the identification of polymerase chain reaction (PCR) or combined with clinical features and Genome-Wide Analysis.

With the advantages of inocula consistency and ease of manipulation, a variety of genetic C. pneumoniae vaccines have been developed for decades, the data show that various candidate genes, such as DnaX2, CPn0884, and CPn0913, have been widely used in C. pneumoniae vaccine development. Meanwhile, recent studies demonstrate that a DNA vaccine using the heat shock protein 60 (HSP-60) gene of C. pneumoniae exhibits a protective efficacy against infection in C57Bl/6 mice model. In addition, studies also show a CD8 T cell heptaepitope minigene vaccine should be useful to prevent C. pneumoniae infections in mice models.

Our Services for Chlamydiae pneumoniae Vaccines

The Picture of Chlamydiae pneumoniae – Creative Biolabs

Our platform provides the state-of-art services for any Chlamydiae pneumoniae vaccines development project. Our scientists specialized in vaccine studies will work with you to develop the most appropriate strategy that will offer the most meaningful data for your research.

One-stop vaccine development solution
Cost-saving discovery strategy
Mature vaccine technology platform

Creative Biolabs is recognized as the world leader for providing vaccine development services for years. We have developed efficient protocols for Chlamydiae pneumoniae vaccines development. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.